MedTrace Logo

Optivate in People With Von Willebrand Disease Undergoing Surgery

NCT00404300 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2010-03-03

No results posted yet for this study

Summary

An open, multi-centre study in patients with von Willebrand Disease (VWD) undergoing surgery.

Conditions

  • Von Willebrand Disease

Interventions

DRUG

Optivate

Plasma-derived Factor VIII

Sponsors & Collaborators

  • Bio Products Laboratory

    lead OTHER

Principal Investigators

  • Thynn Thynn Yee · Royal Free Hospital NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Completion
2008-09-30

Countries

  • Israel
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00404300 on ClinicalTrials.gov